

DAFTAR PUSTAKA

- A. Cortegiani, M. Ippolito, M. Greco, V. Granone, A. Protti, C. Gregoretti, A. Giarratano, S. Einav, M. C. (2020) 'Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review', (January).
- Belletti, A. *et al.* (2021) 'Efficacy and safety of IL-6 inhibitors in patients with COVID-19 pneumonia: a systematic review and meta-analysis of multicentre, randomized trials', *Annals of Intensive Care*. Springer International Publishing, 11(1). doi: 10.1186/s13613-021-00941-2.
- Berardicurti, O. *et al.* (2020) 'Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis', *Clinical and experimental rheumatology*. NLM (Medline), 38(6), pp. 1247–1254.
- Bergmann, C. C. and Silverman, R. H. (2020) 'COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies', *Cleveland Clinic Journal of Medicine*, 87(5), pp. 321–327. doi: 10.3949/CCJM.87A.20047.
- Bohn, M. K. *et al.* (2021) 'Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression', (89), pp. 288–301. doi: 10.1152/physiol.00019.2020.
- Cao, M. *et al.* (2020) 'Clinical Features of Patients Infected with the 2019 Novel Coronavirus (COVID-19) in Shanghai, China', *medRxiv*, pp. 1–30.
- Chakraborty, C. *et al.* (2020) 'COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients', *Journal of Medical Virology*. John Wiley and Sons Inc, 92(11), pp. 2260–2262. doi: 10.1002/JMV.26078.
- Channappanavar, R. *et al.* (2019) 'IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes', *Journal of*

- Clinical Investigation*, 129(9), pp. 3625–3639. doi: 10.1172/JCI126363.
- Chen, G. *et al.* (2020) ‘Clinical and immunological features of severe and moderate coronavirus disease 2019’, *The Journal of Clinical Investigation*. American Society for Clinical Investigation, 130(5), pp. 2620–2629. doi: 10.1172/JCI137244.
- Coomes, E. A. and Haghbayan, H. (2020) ‘Interleukin-6 in Covid-19: A systematic review and meta-analysis’, *Reviews in Medical Virology*. John Wiley and Sons Ltd, 30(6), pp. 1–9. doi: 10.1002/RMV.2141.
- Coperchini, F. *et al.* (2020) ‘The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system’, *Cytokine and Growth Factor Reviews*. Elsevier, 53(May), pp. 25–32. doi: 10.1016/j.cytogfr.2020.05.003.
- COVID-19 Treatment Guidelines Panel. (2020) ‘Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Disponible en: <https://covid19treatmentguidelines.nih.gov/>.’, *National Institute of Health*, 2019, p. 130. Available at: <https://www.covid19treatmentguidelines.nih.gov/>.
- Cui, J., Li, F. and Shi, Z. L. (2019) ‘Origin and evolution of pathogenic coronaviruses’, *Nature Reviews Microbiology*. Springer US, 17(3), pp. 181–192. doi: 10.1038/s41579-018-0118-9.
- Gao, Y. *et al.* (2020) ‘Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19’, *Journal of Medical Virology*. John Wiley & Sons, Ltd, 92(7), pp. 791–796. doi: 10.1002/JMV.25770.
- Gordon, A.C.; Mouncey, P.R.; Al-Beidh, F.; Rowan, K.M.; Nichol, A.D.; Arabi, Y.M.; Annane, D.; Beane, A.; Berry, L.R.; Bhimani, Z.; Bonten, M. J. *et al.* (2021) ‘Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19’, *New England Journal of Medicine*, 384(16), pp. 1491–1502. doi: 10.1056/nejmoa2100433.

- Guan, W. *et al.* (2020) ‘Clinical characteristics of coronavirus disease 2019 in China’, *New England Journal of Medicine*, 382(18), pp. 1708–1720. doi: 10.1056/NEJMoa2002032.
- Hamed, D. M. *et al.* (2021) ‘Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison’. Elsevier BV, 14(8), pp. 985–989. doi: 10.1016/J.JIPH.2021.06.003.
- Hermine, O. *et al.* (2020) ‘Effect of Tocilizumab vs Usual Care in Adults Hospitalized with COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial’, *JAMA Internal Medicine*, 181(1), pp. 32–40. doi: 10.1001/jamainternmed.2020.6820.
- Hermine, O. *et al.* (2021) ‘Effect of Tocilizumab vs Usual Care in Adults Hospitalized with COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial’, *JAMA Internal Medicine*, 181(1), pp. 32–40. doi: 10.1001/jamainternmed.2020.6820.
- Högner, K. *et al.* (2013) ‘Macrophage-expressed IFN- β Contributes to Apoptotic Alveolar Epithelial Cell Injury in Severe Influenza Virus Pneumonia’, *PLoS Pathogens*, 9(2). doi: 10.1371/journal.ppat.1003188.
- Khan, F. A. *et al.* (2021) ‘Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19’, *Thorax*, 76(9), pp. 907–919. doi: 10.1136/thoraxjnl-2020-215266.
- Khiali, S., Khani, E. and Entezari-Maleki, T. (2020) ‘A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome’, *Journal of Clinical Pharmacology*. Blackwell Publishing Inc., 60(9), pp. 1131–1146. doi: 10.1002/JCPH.1693.
- Landray, M. J. *et al.* (2021) ‘Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform

- trial', *The Lancet Respiratory Medicine*, 9(12), pp. 1419–1426. doi: 10.1016/S2213-2600(21)00435-5.
- León López, R. *et al.* (2020) 'Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): Protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial', *BMJ Open*. BMJ Publishing Group, 10(11). doi: 10.1136/BMJOPEN-2020-039951.
- Liberati, A. *et al.* (2009) 'The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.', *BMJ (Clinical research ed.)*, 339. doi: 10.1136/bmj.b2700.
- Liu, B. *et al.* (2020) 'Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?', *Journal of Autoimmunity*. Academic Press, 111. doi: 10.1016/J.JAUT.2020.102452.
- Manirul Haque, S. *et al.* (no date) 'A comprehensive review about SARS-CoV-2'. doi: 10.2217/fvl-2020-0124.
- Martin, A. J. and Jans, D. A. (2021) 'Antivirals that target the host IMP α / β 1-virus interface', *Biochemical Society Transactions*. Portland Press Ltd, pp. 281–295. doi: 10.1042/BST20200568.
- McGonagle, D. *et al.* (2020) 'The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease', *Autoimmunity Reviews*. Elsevier, 19(6), p. 102537. doi: 10.1016/j.autrev.2020.102537.
- Meanwatthana, J. and Majam, T. (2021) 'Interleukin-6 Antagonists: Lessons From Cytokine Release Syndrome to the Therapeutic Application in Severe COVID-19 Infection'. doi: 10.1177/08971900211000691.

- Michailidou, A., Trenz, H.-J. and de Wilde, P. (2019) ‘Annex I’, *The Internet and European Integration*, pp. 167–172. doi: 10.2307/j.ctvdf0dxq.12.
- Ministry of Health and Family Welfare India (2021) ‘AIIMS / ICMR-COVID-19 National Task Force / Joint Monitoring Group (Dte . GHS) Ministry of Health & Family Welfare , Government of India Mild disease Severe disease’, (April), p. 2021. Available at: <https://covid.aiims.edu/clinical-guidance-for-management-of-adult-covid-19-patients/>.
- Mission, W. C. J. (2020) *Report of the WHO-China joint mission on coronavirus disease 2019 (covid-19)*.
- Nugroho, C. W. *et al.* (2021) ‘Optimal use of tocilizumab for severe and critical COVID-19: A systematic review and meta-analysis’, *F1000Research*. F1000 Research Ltd, 10. doi: 10.12688/F1000RESEARCH.45046.1.
- Paccaly, A. J. *et al.* (2021) ‘Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate’, *Journal of Clinical Pharmacology*, 61(1), pp. 90–104. doi: 10.1002/jcph.1703.
- Patel, S., Saxena, B. and Mehta, P. (2021) ‘No Title’, *Heliyon*. Elsevier Ltd, 7(2), p. e06158. doi: 10.1016/J.HELIYON.2021.E06158.
- PDPI *et al.* (2020) *Pedoman tatalaksana COVID-19 Edisi 3 Desember 2020, Pedoman Tatalaksana COVID-19*. Available at: <https://www.papdi.or.id/download/983-pedoman-tatalaksana-covid-19-edisi-3-desember-2020>.
- Pelaia, C. *et al.* (2021) ‘Therapeutic role of tocilizumab in sars-cov-2-induced cytokine storm: Rationale and current evidence’, *International Journal of Molecular Sciences*. MDPI AG, 22(6), pp. 1–16. doi: 10.3390/IJMS22063059.

- Potere, N. *et al.* (2021) ‘The role of IL-6 and IL-6 blockade in COVID-19’, *Expert Review of Clinical Immunology*. Taylor and Francis Ltd. doi: 10.1080/1744666X.2021.1919086.
- Ragab, D. *et al.* (2020a) ‘The COVID-19 Cytokine Storm; What We Know So Far’, *Frontiers in Immunology*. Frontiers Media S.A., 11. doi: 10.3389/FIMMU.2020.01446.
- Ragab, D. *et al.* (2020b) ‘The COVID-19 Cytokine Storm; What We Know So Far’, *Frontiers in Immunology*, 11(June), pp. 1–4. doi: 10.3389/fimmu.2020.01446.
- Rakoshitz, G. (2000) ‘Immunoregulation, Tolerance, and Therapeutic Immunology’. doi: 10.1016/B978-0-12-198382-6.50038-8.
- Ramiro, S. *et al.* (2020) ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: Results of the CHIC study’, *Annals of the Rheumatic Diseases*. BMJ Publishing Group, 79(9), pp. 1143–1151. doi: 10.1136/ANNRHEUMDIS-2020-218479.
- Rizk, J. G. *et al.* (2020) ‘Pharmaco-Immunomodulatory Therapy in COVID-19’, *Drugs*. Adis, 80(13), pp. 1267–1292. doi: 10.1007/S40265-020-01367-Z.
- Rosas, I. O. *et al.* (2020) ‘Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia’, *medRxiv*, (165), pp. 1–13.
- Rutgers, A. *et al.* (2021) ‘Timely administration of tocilizumab improves survival of hospitalized COVID-19 patients’, 1(3394).
- Saeed, A. F. U. H. *et al.* (2017) ‘Antibody Engineering for Pursuing a Healthier Future’, *Frontiers in Microbiology*, 8(MAR), pp. 1–28. doi: 10.3389/fmicb.2017.00495.
- Salama, C. *et al.* (2020) ‘Tocilizumab in Patients Hospitalized with Covid-19

- Pneumonia', *New England Journal of Medicine*, 384(1), pp. 20–30. doi: 10.1056/nejmoa2030340.
- Satheka, A. C. and Tesfamariam, A. M. (2020) 'Evaluation of the Progression of Hybridoma Technology: Methods, Applications, Advantages and Drawbacks', *Journal of Genetic Disorders & Genetic Reports*, Volume 9(Issue 2). doi: 10.37532/jgdgr.2020.9(2).184.
- Shekhawat, J. *et al.* (2021) 'Interleukin-6 Perpetrator of the COVID-19 Cytokine Storm'. Springer Science and Business Media LLC, pp. 1–11. doi: 10.1007/S12291-021-00989-8.
- Sivapalasingam, S. *et al.* (2021) 'A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19'.
- Soin, A. S. *et al.* (2021) 'Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial', *The Lancet. Respiratory medicine*. NLM (Medline), 9(5), pp. 511–521. doi: 10.1016/S2213-2600(21)00081-3.
- Stone, J. H. *et al.* (2020) 'Efficacy of Tocilizumab in Patients Hospitalized with Covid-19', *New England Journal of Medicine*, 383(24), pp. 2333–2344. doi: 10.1056/nejmoa2028836.
- Susilo, A. *et al.* (2020) 'Coronavirus Disease 2019: Tinjauan Literatur Terkini', *Jurnal Penyakit Dalam Indonesia*, 7(1), p. 45. doi: 10.7454/jpdi.v7i1.415.
- Talashian, M. *et al.* (2021) '[Pre-print] Tocilizumab Failed to Reduce Mortality in Severe COVID-19 Patients: Results From a Randomized Controlled Clinical Trial'. Available at: <https://doi.org/10.21203/rs.3.rs-463921/v1>.
- Taylor, P. C. *et al.* (2021) 'Neutralizing monoclonal antibodies for treatment of COVID-19', *Nature Reviews Immunology*. Springer US, 21(6), pp. 382–393. doi: 10.1038/s41577-021-00542-x.

Shofiyah Hasya, 2022

EFIKASI ANTI IL-6 RECEPTOR MONOCLONAL ANTIBODY SEBAGAI TERAPI ADJUVAN PADA PASIEN COVID-19 DENGAN CYTOKINE RELEASE SYNDROME: Sebuah Tinjauan Sistematis

UPN Veteran Jakarta, Fakultas Kedokteran, Program Studi Kedokteran Program Sarjana

[www.upnvj.ac.id – www.library.upnvj.ac.id – www.repository.upnvj.ac.id]

- The Cochrane Collaboration (2019) ‘RoB 2 Guidance: Parallel Trial’, (July), pp. 1–24. Available at: <https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials>.
- Veiga, V. C. *et al.* (2021) ‘Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: Randomised controlled trial’, *The BMJ*, 372. doi: 10.1136/bmj.n84.
- Wan, S. *et al.* (2020) ‘Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)’, *medRxiv*. Cold Spring Harbor Laboratory Press, p. 2020.02.10.20021832. doi: 10.1101/2020.02.10.20021832.
- Wang, D. *et al.* (2021) ‘Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial’. Higher Education Press Limited Company, 15(3), pp. 486–494. doi: 10.1007/S11684-020-0824-3.
- WHO Indonesia (2021) ‘Coronavirus Disease 2019 (COVID-19) Coronavirus Coronavirus Disease Disease Situation World Health World Health Organization Organization 28 April 2021’, 53, pp. 1–11.
- World Health Organization, W. (2021) *WHO Coronavirus disease (COVID-19) dashboard*.
- Wu, C. *et al.* (2020) ‘Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China’, *JAMA Internal Medicine*, 180(7), pp. 934–943. doi: 10.1001/jamainternmed.2020.0994.
- Xu, X. *et al.* (2020) ‘Effective treatment of severe COVID-19 patients with tocilizumab’, *Proceedings of the National Academy of Sciences of the United States of America*. National Academy of Sciences, 117(20), pp. 10970–10975. doi: 10.1073/PNAS.2005615117.

- Yang, L. *et al.* (2021) ‘The signal pathways and treatment of cytokine storm in COVID-19’, *Signal Transduction and Targeted Therapy*. Springer US, 6(1), pp. 1–20. doi: 10.1038/s41392-021-00679-0.
- Ye, Q., Wang, B. and Mao, J. (2020) ‘The pathogenesis and treatment of the “Cytokine Storm” in COVID-19”, *Journal of Infection*. Elsevier Ltd, 80(6), pp. 607–613. doi: 10.1016/j.jinf.2020.03.037.
- Zhou, Z. and Price, C. C. (2020) ‘Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease’, *Expert Opinion on Investigational Drugs*. Taylor and Francis Ltd., 29(12), pp. 1407–1412. doi: 10.1080/13543784.2020.1840549.
- Zhu, N. *et al.* (2020) ‘A Novel Coronavirus from Patients with Pneumonia in China, 2019’, *New England Journal of Medicine*. Massachusetts Medical Society, 382(8), pp. 727–733. doi: 10.1056/NEJMOA2001017.